Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Phentermine has been the most commonly prescribed weight loss medication in the United States for decades. Semaglutide is newer, more effective on paper, but much more expensive. If you’re comparing the two — or wondering why your doctor is recommending one over the other — here’s the complete breakdown.
Semaglutide vs Phentermine: Head-to-Head
| Semaglutide (Wegovy/Ozempic) | Phentermine | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Sympathomimetic stimulant (Schedule IV) |
| How it works | Mimics GLP-1 hormone: reduces appetite, slows digestion, improves insulin sensitivity | Stimulates CNS to suppress appetite via norepinephrine release |
| Administration | Weekly subcutaneous injection | Daily oral pill or capsule |
| Average weight loss | 15–17% of body weight (68 weeks) | 5–7% of body weight (12 weeks typical) |
| FDA approval | Approved for chronic weight management | Approved for short-term use only (12 weeks) |
| Cost (monthly) | $1,000–$1,400 brand; $150–$400 compounded | $15–$50 generic |
| Insurance coverage | Limited; often requires prior auth | Usually covered or very low cost |
| Main side effects | Nausea, vomiting, constipation, fatigue | Increased heart rate, dry mouth, insomnia, anxiety, elevated blood pressure |
| Cardiovascular safety | Proven cardiovascular benefit (SELECT trial) | Cardiovascular risk in certain populations; not for heart disease patients |
| Diabetes benefit | Yes — improves blood sugar significantly | Minimal direct glucose effect |
| Long-term use | Approved for indefinite use | Not approved long-term; dependency concern |
| Muscle loss | Moderate (~38% lean mass of weight lost) | Limited data; caloric restriction applies |
How Each Drug Works
Semaglutide
Semaglutide is a GLP-1 receptor agonist — it mimics a hormone your gut naturally releases after eating. It works through multiple mechanisms: slowing how quickly your stomach empties (which increases fullness), signaling your brain’s satiety center to reduce hunger and “food noise,” and improving insulin sensitivity. It also has meaningful cardiovascular benefits shown in large trials.
The effects build gradually over weeks to months as the dose escalates. This makes the first month underwhelming but months 3–12 quite powerful.
Phentermine
Phentermine is a stimulant — structurally related to amphetamines — that works by triggering norepinephrine release in the brain, which suppresses appetite quickly and increases energy expenditure. It works fast (effects within hours) and is cheap, which explains its decades of popularity.
However, it’s only FDA-approved for short-term use (12 weeks), carries cardiovascular risks, can cause dependence, and produces significantly less weight loss than semaglutide over comparable periods.
Weight Loss Comparison
The weight loss gap between these medications is significant:
- Phentermine: Clinical trials show 5–7% body weight loss over 12 weeks. Long-term data is limited because it’s not approved for long-term use.
- Semaglutide 2.4 mg (Wegovy): STEP 1 trial showed 15.3 kg (~33 lb) average loss at 68 weeks — approximately 15% of starting body weight. Top quartile responders lost 25%+.
For a 250 lb person: phentermine might produce 13–17 lbs of loss; semaglutide might produce 35–45+ lbs over a full year.
Side Effect Profiles
| Side Effect | Semaglutide | Phentermine |
|---|---|---|
| Nausea | Very common (early, usually resolves) | Uncommon |
| Increased heart rate | Slight increase possible | Common; significant in some |
| Insomnia | Uncommon | Very common |
| Anxiety/jitteriness | Uncommon | Common |
| Dry mouth | Occasional | Very common |
| Elevated blood pressure | Slight decrease typical | Can increase significantly |
| Constipation | Common | Occasional |
| Dependence risk | None established | Schedule IV controlled substance |
Who Should Consider Each
| Situation | Better Choice | Why |
|---|---|---|
| Need to lose 20+ lbs long-term | Semaglutide | Far greater efficacy for significant weight loss |
| Have type 2 diabetes or prediabetes | Semaglutide | Direct glucose-lowering benefit |
| Cardiovascular disease history | Semaglutide | Phentermine is contraindicated with heart disease; semaglutide has proven CV benefit |
| Cost is the primary barrier | Phentermine (or compounded sema) | $15–50/month vs $150–1400/month |
| Anxiety or high blood pressure | Semaglutide | Phentermine worsens both conditions |
| Need rapid initial results | Phentermine (short-term) | Works within days; sometimes used as bridge |
| Short-term kickstart needed | Phentermine alone or phentermine/topiramate | Fast-acting; doesn’t require weekly injection |
Can You Take Both Together?
Some obesity medicine physicians prescribe phentermine alongside a GLP-1 medication short-term — particularly during the early dose escalation phase when semaglutide effects are still building. However, this is off-label and carries additive cardiovascular risk. It’s not a standard approach and shouldn’t be done without close medical supervision.
The Bottom Line
If efficacy is the priority and cost isn’t a prohibitive barrier, semaglutide wins by a wide margin — it produces roughly twice to three times the weight loss, has proven long-term safety, cardiovascular benefits, and no dependency risk. Phentermine remains relevant where cost is a genuine barrier, for very short-term kickstart use, or in patients who aren’t candidates for GLP-1 medications.
The good news: compounded semaglutide has dramatically changed the cost equation. At $150–$250/month from telehealth platforms, the gap between phentermine’s accessibility and semaglutide’s efficacy is narrower than it’s ever been.
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.
📋 Compare Top GLP-1 Providers — Find Your Best Option
